Clinical Trials Logo

Clinical Trial Summary

The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00770341
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date September 2008
Completion date February 2010

See also
  Status Clinical Trial Phase
Withdrawn NCT02899702 - Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children Phase 4
Completed NCT00352612 - Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Phase 4
Completed NCT00279864 - The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection N/A
Completed NCT00735839 - V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED) Phase 1
Completed NCT00814151 - MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial N/A
Completed NCT02812446 - Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development N/A
Completed NCT00846105 - Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA) N/A
Completed NCT02284555 - Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment) Phase 4
Completed NCT01592214 - Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 Phase 1
Completed NCT01827358 - Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants Phase 2
Completed NCT00729937 - Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA" Phase 2/Phase 3
Completed NCT00730028 - Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus Phase 2